Geneva, June 30 -- International Clinical Trials Registry received information related to the study (PACTR202506834698530) titled 'Novel phytopharmaceutical alpha linolenic acid 18n:3 nanoformulation for symptomatic treatment of acute and chronic pain in homozygous HbSS sickle cell disease patients' on June 20.
Study Type: Interventional
Study Design:
Factorial: participants randomly allocated to either no, one, some or all interventions simultaneously,Randomised,Simple randomization using a randomization table created by a computer software program,Numbered containers
Primary Sponsor: Saarland University
Condition:
Haematological Disorders
Haematological Disorders
Intervention:
ALADRE SOULAGE 1
Placebo SOULAGE 1
ALADRE SOULAGE 2...